Tissue Gene Announces Regulatory Allowance order phase IIa study with TG – C in South Korea launch for osteoarthritis of the kneeTissue genes, announced that its South Korean licensing partner Kolon Life Science, has regulatory allowance from the received Korea Food and Drug Administration to initiate a Phase IIa study in tissue Gene – C in patients with severe osteoarthritis of the knee. TG-C was used for the localized delivery of allogeneic human cells expressing TGF – beta1, developed by regeneration of cartilage..
About Tissue genes,. Tissue Gene , a Maryland resident biopharmaceutical company focused with a strong global vision on the development of a proprietary and innovative suite of regenerative orthopedic therapeutic products Founded in 1999, the company is the primary pipeline on the treatment and regeneration of damaged cartilage, bone, disc and nerves concentrated. The core technology employed the form of cell-mediated gene therapy to known therapeutic proteins to localized areas of damaged tissue to deliver. Continue reading